Log In
BCIQ
Print this Print this
 

MEDI4166

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionPCSK9/GLP-1 mAb and peptide fusion
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9) ; Glucagon-like peptide-1 (GLP-1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today